Bryant Furlow, Author at Cancer Therapy Advisor

Bryant Furlow

Bryant Furlow is medical journalist working at the crossroads of research, clinical practice, and public policy. His work has appeared The Lancet, New Scientist, and Oncology Nurse Advisor.

All articles by Bryant Furlow

Researchers proposed lowering the circulating plasma cell threshold from 20% to 5% for plasma cell l

clonoSEQ and MRD Testing in Multiple Myeloma and ALL

Medicare coverage has been announced for Adaptive Biotechnologies’ clonoSEQ® next-generation sequencing assay for the detection of minimal residual disease (MRD) after treatment for multiple myeloma or B-cell acute lymphoblastic leukemia (ALL) — a key step toward its use for patient care in cancer clinics in the United States.1,2The FDA announced regulatory approval for the assay…

Next post in Lung Cancer